Paper Details

  1. Home
  2. Paper Details

Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.

Author: ZhangDazhi, ZhangQiongfang, ZhangQiongyue, ZhuFeng

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study aims to evaluate the effectiveness of combination therapy (interferon (IFN) plus nucleos(t)ide analogues (NAs)) compared to IFN monotherapy in achieving hepatitis B e-antigen (HBeAg) seroconversion or seroclearance in HBeAg-positive chronic hepatitis B (CHB) patients.
Paper Details　
Original Abstract of the Article :
Recent available treatment guidelines are pointing up clearance or seroconversion of hepatitis B e-antigen (HBeAg) as a valuable endpoint in treating HBeAg-positive chronic hepatitis B (CHB) patients. To evaluate the effect of combination therapy [interferon (IFN) plus nucleos(t)ide analogues (NAs)]...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.micpath.2019.103912

データ提供：米国国立医学図書館（NLM）

Hepatitis B Treatment: A Meta-analysis of IFN Monotherapy vs. Combined Therapy

Chronic hepatitis B (CHB) is a serious liver infection that can lead to cirrhosis and liver cancer. Treatment goals often include achieving HBeAg seroconversion or seroclearance, which indicate a reduction in viral activity. This meta-analysis examines the effectiveness of interferon (IFN) monotherapy versus combined therapy (IFN plus nucleos(t)ide analogues [NAs]) in achieving HBeAg seroconversion or seroclearance in HBeAg-positive CHB patients.

Combined Therapy Shows Promise for HBeAg Clearance

The meta-analysis revealed that combined therapy (IFN plus NAs) was associated with a higher rate of HBeAg seroconversion or seroclearance compared to IFN monotherapy. This finding suggests that combined therapy may be a more effective treatment strategy for achieving sustained viral suppression in HBeAg-positive CHB patients.

Optimizing Hepatitis B Treatment Strategies

This meta-analysis highlights the importance of considering different treatment strategies for chronic hepatitis B. By carefully evaluating the benefits and risks of various treatment approaches, healthcare professionals can tailor treatment plans to optimize outcomes for individual patients. Just as a skilled desert navigator selects the most efficient route to their destination, clinicians should consider the unique needs of each patient when choosing hepatitis B treatment strategies.

Dr. Camel's Conclusion

This meta-analysis provides valuable insights into the effectiveness of different treatment strategies for chronic hepatitis B. The findings suggest that combined therapy (IFN plus NAs) may be more effective in achieving HBeAg seroconversion or seroclearance compared to IFN monotherapy. This research underscores the importance of individualized treatment approaches and the ongoing need for research to refine and improve treatment strategies for chronic hepatitis B.

Date :
  1. Date Completed 2020-10-26
  2. Date Revised 2020-10-26
Further Info :

Pubmed ID

31816402

DOI: Digital Object Identifier

10.1016/j.micpath.2019.103912

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.